A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight used it ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may ...

Please provide your email address to receive an email when new articles are posted on . Men with metabolic hypogonadism had larger increases in testosterone levels with tirzepatide vs. testosterone ...

Overweight and obese patients taking weight loss and diabetes drug tirzepatide—the generic name for Mounjaro and Zepbound—saw significant reductions in their blood pressure, according to a new study ...

A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant weight loss in obese mice but also slashed breast cancer tumor growth. The ...

Compared with placebo, tirzepatide was associated with a slower decline in eGFR among patients with prediabetes and overweight or obesity. Tirzepatide improves kidney outcomes among patients with ...

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity ...

The Food and Drug Administration said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and ...

The Food and Drug Administration (FDA) recently removed Eli Lily's weight-loss drug from its shortage list, which some industry officials and medical experts argue will complicate access for some ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...